Navigation Links
Organovo Reports Q1 Fiscal 2014 Results, Provides Business Update

SAN DIEGO, Aug. 12, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo") a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, has reported on its financial results for the three-month period ended June 30, 2013 and provides a business update.

Recent Corporate Highlights

  • Presented data on first fully cellular 3D Bioprinted Liver Tissue
  • Listed common stock on the NYSE MKT
  • Successfully completed $46.6 million public offering
  • Appointed Tamar D. Howson to the Company's Board of Directors 
  • Nominated Richard Heyman Ph.D. for election to the Board of Directors at the upcoming Annual Meeting
  • Changed fiscal year-end from December 31st to March 31st
  • Organovo and Methuselah Foundation Announced Funding of Bioprinting Research at Research Institutions
  • On April 26th, Organovo described the first fully cellular 3D bioprinted liver tissue, having presented data on its  in vitro three-dimensional liver at the 2013 Experimental Biology conference in Boston, Massachusetts. For the first time, human liver tissues were generated that were truly three-dimensional, being up to 500 microns in thickness in the smallest dimension, and consisting of multiple cell types arranged in defined spatial patterns that reproduce key elements of native tissue architecture and demonstrated excellent functional characteristics that replicates human biology better than what has come before. 

    On July 9th, Organovo announced that its common stock had been approved for listing on the New York Stock Exchange MKT.  Trading commenced on the NYSE MKT on July 11th, and Company's CEO Keith Murphy rang the opening bell at the NYSE on July 15 th.

    On August 7 th, Organovo successfully completed a public offering in which it raised gross proceeds of $46.6 million through the issuance of 10,350,000 shares of its common stock.

    On June 10th, Organovo announced the appointment of Tamar D. Howson to its Board of Directors.  Ms. Howson is a seasoned business development executive within the pharmaceutical industry, having formerly served as senior vice president of both Bristol-Meyers Squibb and SmithKline Beecham.  She currently serves as a business development and strategy consultant to biopharmaceutical companies.  She also serves as a director at Idenix, Oxigene Pharmaceuticals, and Warner Chilcott.

    On July 18th, Organovo announced that Richard A. Heyman, Ph.D. had been nominated to be elected to the Company's Board of Directors at the Annual Meeting of Shareholders scheduled to be held on August 21, 2013. Dr. Heyman is an experienced life science executive who is currently chief executive officer of Aragon Pharmaceuticals, which he co-founded in 2009.  In June 2013, Aragon announced a definitive agreement with Johnson and Johnson whereby Aragon will be acquired for up to $1 billion dollars in total transaction value.  Previously, Dr. Heyman was Chief Scientific Officer at Kalypsys, Inc.

    On April 3rd, Organovo announced a fiscal year-end change from December 31st to March 31st, in alignment with its intention to list its common stock on a U.S. exchange at the earliest available opportunity.

    On July 24th, Organovo announced that Methuselah Foundation has initiated a campaign in which it will fund research at major research institutions using Organovo's proprietary NovoGen Bioprinting technology. The program will feature grants of research funding from the non-profit Methuselah Foundation to major academic research centers engaged in cutting-edge biomedical research.  Eligible institutions will include public and private research universities and private non-profit research institutes.  Under the program, Methuselah Foundation will divide a donation of at least $500,000 in direct funding for research projects across several institutions. 

    "Organovo has consistently and effectively executed its business plan from both a technology and business perspective," stated Keith Murphy, chief executive officer of Organovo. "Following our recent capital raise, we are well positioned to grow long-term shareholder value through development and launch of our first commercial product in 2014, through the capture of additional collaborative partnerships, and through expanded investment in the development of therapeutic tissues intended for implantation."

    Financial Results
    For the three months ended June 30, 2013, total revenues of approximately $0.1 million were $0.2 million or 67% below the approximately $0.3 million in revenues for the same period in 2012. This decrease reflects the planned phasing of deliverables under the original project scope of our collaborative arrangements despite current overall increases in collaborative research activities. The Company is increasing its internal investment in these collaborative activities with the intention of accelerating the growth of shareholder value.

    Operating expenses increased approximately $2.1 million or 124% in the three months ended June 30, 2013 over the same period in 2012, from approximately $1.7 million in 2012 to $3.8 million in 2013. Most significantly, relative to the same period in the prior year, the Company invested in building its research, development and administrative staff, increasing its headcount from 21 full-time employees as of June 30, 2012 to 35 full-time employees as of June 30, 2013, including 24 employees within research and development.  Consequently payroll and benefits expenses increased by approximately $0.5 million or 70% over the same period in 2012, and stock-based compensation increased from under $0.1 million to $0.8 million for the same periods. To accommodate our growing research and development needs the Company relocated to a larger space, tripling our facilities related expenses when compared to prior periods.  With the increased research and development activity and output, inputs such as lab supplies and contracted services increased across the board.  Finally, the Company incurred approximately $0.3 million more in external expenses related to public company status versus the same period, prior year, in addressing SEC financial reporting, investor relations, corporate governance and audit requirements.

    The approximate $33.9 million decrease in other expense for the three month period ending June 30, 2013 compared to the same period of the prior year, was primarily related to 2012 non-cash transaction costs associated with the warrants issued in our 2012 Private Placement.  Due to the majority of the underlying warrants being exercised prior to June 30, 2013, or modified and reclassified to equity, the net warrant derivative liability was substantially less than in the same period of 2012 due to significantly fewer underlying warrants. 

    The Company also had negative cash flow from operations of $2.7 million during the three months ended June 30, 2013, with end-of-period cash and cash equivalents of approximately $12.8 million and an accumulated deficit of $70.1 million.  At June 30, 2012, the Company had cash and cash equivalents of approximately $8.5 million and an accumulated deficit of $79.2 million.  At June 30, 2013, the Company had total current assets of approximately $13.3 million and current liabilities of approximately $7.6 million, resulting in working capital of $5.7 million. At June 30, 2012, we had total current assets of approximately $9.2 million and current liabilities of approximately $0.9 million, resulting in working capital of $8.3 million.  Subsequently, on August 7, 2013, the Company sold 10,350,000 shares of the Company's common stock, with net proceeds to the Company of approximately $43.3 million, after deducting underwriting discounts and commissions and estimated offering expenses of $3.3 million.

    As of June 30, 2013, the Company had 64,951,014 total issued and outstanding shares of Common Stock, and five year warrants for the opportunity to purchase an additional 3,481,760 shares of Common Stock at exercise prices between $0.85 and $1.00 per share and 550,000 warrants with terms between two and five years and exercise prices between $2.21 and $3.24 per share.
    Subsequent to June 30, 2013, the Company had 1,242,478 warrants exercised on a cashless basis, for a net issuance of 981,055 shares and 225,000 warrants exercised for 225,000 common shares for cash proceeds to the Company of $609,000.  In aggregate, issued and outstanding common stock, shares underlying outstanding warrants, and shares reserved for the 2008 and 2012 incentive plans total 74,267,596 shares of common stock as of June 30, 2013.

    About Organovo Holdings, Inc. 
    Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at

    Safe Harbor Statement 
    Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology;; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our report on Form 10-Q filed August 9, 2013, the prospectus supplement filed with the SEC on August 2, 2013 and the transition report on Form 10-KT filed with the SEC on May 24, 2013 and our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

     Organovo Holdings, Inc.
    (A development stage company)
    Condensed Consolidated Balance Sheets
    (in thousands except per share data)June 30, 2013March 31, 2013(Unaudited)(Audited)AssetsCurrent AssetsCash and cash equivalents$


    15,628Grant receivable—101Inventory8588Prepaid expenses and other current assets327327Total current assets13,26116,144Fixed Assets - Net1,1131,045Restricted Cash3888Other Assets - Net9698Total assets$


    17,375Liabilities and Stockholders' EquityCurrent LiabilitiesAccounts payable$


    641Accrued expenses1,143780Deferred revenue2853Capital lease obligation, current portion1010Warrant liabilities6,0256,898Total current liabilities7,5808,382Deferred revenue, net of current portion89Capital lease obligation, net of current portion1215Total liabilities$


    8,406Commitments and Contingencies (Note 5)Stockholders' EquityCommon stock, $0.001 par value; 150,000,000 shares authorized, 64,951,014 and 64,686,919 shares issued and outstanding at June 30, 2013 and March 31, 2013, respectively6565Additional paid-in capital76,97975,269Deficit accumulated during the development stage(70,136)(66,365)Total stockholders' equity6,9088,969Total Liabilities and Stockholders' Equity$



     Organovo Holdings, Inc.
    (A development stage company)
    Unaudited Condensed Consolidated Statements of Operations
    (in thousands except per share data)Three Months Ended
    June 30, 2013Three Months Ended
    June 30, 2012Period from
    April 19, 2007
    June 30, 2013



    224Collaborations942591,990Grants12—955Total Revenues1062593,169Cost of product revenue——134Selling, general, and administrative expenses2,3781,05614,917Research and development expenses1,4626539,544Loss from Operations(3,734)(1,450)(21,426)Other Income (Expense)Fair value of warrant liabilities in excess of proceeds received——(19,019)Change in fair value of warrant liabilities(23)(33,937)(21,995)Financing transaction costs in excess of proceeds received——(2,130)Loss on inducement to exercise warrants——(1,904)Loss on disposal of fixed assets(4)—(162)Interest expense(13)—(3,484)Interest income3214Other expense——(30)Total Other Income (Expense)(37)(33,935)(48,710)Net Loss$



    (70,136)Net loss per common share - basic and diluted$


    (0.82)Weighted average shares used in computing net loss per common share - basic and diluted64,794,14443,029,026 

     Organovo Holdings, Inc.
    (A development stage company)
    Unaudited Condensed Consolidated Statements of Cash Flows (in thousandsThree Months Ended
    June 30, 2013Three Months Ended
    June 30, 2012Period from
    April 19, 2007
    June 30, 2013Cash Flows From Operating ActivitiesNet loss$



    (70,136)Adjustments to reconcile net loss to net cash used in operating activities:Amortization of deferred financing costs——438Amortization of warrants issued for services72—889Depreciation and amortization9320524Loss on disposal of fixed assets4—162Amortization of debt discount——2,084Interest accrued on convertible notes payable——495Fair value of warrant liabilities in excess of proceeds——19,019Change in fair value of warrant liabilities2333,93721,995Loss on inducement to exercise warrants——1,904Expense associated with warrant modification12—77Stock-based compensation802393,102Warrants issued in connection with exchange agreement——528Increase (decrease) in cash resulting from changes in:Grants receivable101——Inventory3(190)(748)Prepaid expenses and other assets(72)(60)(327)Accounts payable(267)(181)374Accrued expenses36351,143Deferred revenue(26)(46)36Net cash used in operating activities(2,663)(1,861)(18,441)Cash Flows From Investing ActivitiesDeposits released from restriction (restricted cash deposits)50(50)(38)Purchases of fixed assets(163)(72)(1,084)Purchases of intangible assets——(114)Net cash used in investing activities(113)(122)(1,236)Cash Flows From Financing ActivitiesProceeds from issuance of convertible notes payable——4,630Proceeds from issuance of common stock and warrants—9928,438Proceeds from exercise of stock options——18Proceeds from issuance of related party notes payable——250Repayment of related party notes payable——(250)Principal payments on capital lease obligation(3)—(12)Repayment of convertible notes and interest payable——(110)Deferred financing costs——(438)Net cash provided by (used in) financing activities(3)9932,526Net Increase (Decrease) in Cash and Cash Equivalents(2,779)(1,884)12,849Cash and Cash Equivalents at Beginning of Period15,62810,353—Cash and Cash Equivalents at End of Period$



    12,849Supplemental Disclosure of Cash Flow Information:Interest$



    10Income Taxes$




    SOURCE Organovo Holdings, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
    2. Organovo Announces the Nomination of Richard A. Heyman to Board of Directors
    3. Organovo Rings Opening Bell On New York Stock Exchange
    4. OTC Markets Group Congratulates Organovo Holdings on Move to NYSE MKT
    5. Organovo To List Common Stock On New York Stock Exchange MKT
    6. Organovo Appoints Tamar D. Howson to Board of Directors
    7. Organovo to Present at the 12th Annual Needham Healthcare Conference
    8. Organovo Partners With ZenBio to Create 3D Tissue Models
    9. Organovo Holdings, Inc. Investor Presentation Now Available for On-demand Viewing at
    10. Organovo Reports Q3 2012 Financial Results, Provides Business Update
    11. Organovo To Present At Lazard Healthcare Conference
    Post Your Comments:
    (Date:11/27/2015)... India , November 27, 2015 /PRNewswire/ ... --> Growing popularity of companion diagnostics ... in cancer biomarkers market with pharmaceutical companies ... in-demand companion diagnostic tests. ... --> Complete report on global cancer ...
    (Date:11/25/2015)... November 25, 2015 2 nouvelles études ... les différences entre les souches bactériennes retrouvées dans ... des êtres humains . Ces recherches  ouvrent une ... la prise en charge efficace de l,un des ... les chats .    --> 2 nouvelles ...
    (Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership between ... (OPBAP) has been formalized with the signing of a Memorandum of Understanding. , ... leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at ...
    (Date:11/24/2015)... ... ... The United States Golf Association (USGA) today announced Dr. Bruce Clarke, of ... since 1961, the USGA Green Section Award recognizes an individual’s distinguished service to the ... of Iselin, N.J., is an extension specialist of turfgrass pathology in the department of ...
    Breaking Biology Technology:
    (Date:11/10/2015)... NEW YORK , Nov. 10, 2015 /PRNewswire/ ... refers to behavioral biometrics that helps to identify ... prevent fraud. Signature is considered as the secure ... for the identification of a particular individual because ... offers more accurate results especially when dynamic signature ...
    (Date:11/9/2015)... Calif. , Nov. 9, 2015  Synaptics Inc. ... interface solutions, today announced broader entry into the automotive ... solutions that match the pace of consumer electronics human ... biometric sensors are ideal for the automotive industry and ... Europe , ...
    (Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
    Breaking Biology News(10 mins):